Patients’ experiences with pre-test genetic counseling provided by breast cancer healthcare professionals: Results from a large prospective multicenter study

Bokkers, Kyra; Bleiker, Eveline M. A.; Velthuizen, Mary E; Koelemij, R.; Burgmans, J.P.J.; Klinkenbijl, J.H.; Velden, Arjan P. Schouten van der; Vermulst, N.; Huizinga, B.F.; Witkamp, Arjen J.; Frakking, T.; Brohet, R.M.; Aalfs, Cora M.; Koole, Wouter; Schoenmaeckers, Ernst J. P.; Ausems, Margreet G. E. M.

doi:10.1016/j.breast.2023.03.017

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Educational tools, automated workflows, and discussions with members of the cancer treatment team (point-of-care testing) are well received and can help increase access to genetic testing of patients with cancer. Point-of-care testing [20][21][22][23][24][25] during regular cancer treatment appointments may also reduce disparities in access to genetic testing. 26,27 However, genetic test results have implications beyond the treatment of the patient's current cancer, and addressing these issues can fall outside the oncology setting.…”

Section: Question: How Can Clinical Oncologists Connect Patients With...mentioning

confidence: 99%

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline Q and A

Kurian,

Bedrosian,

Kohlmann

et al. 2024

JCO Oncol Pract

View full text Add to dashboard Cite

ASCO and the Society of Surgical Oncology (SSO) recently published a joint guideline to provide formal consensus-based recommendations on the role of germline mutation testing in patients with breast cancer. 48 The guideline addressedReasons not to test genes beyond BRCA1/2 might include the higher probability of a variant of uncertain significance result when more genes are tested 14 and the possibility that a patient who is

show abstract

Section: Question: How Can Clinical Oncologists Connect Patients With...mentioning

confidence: 99%

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline Q and A

Kurian,

Bedrosian,

Kohlmann

et al. 2024

JCO Oncol Pract

View full text Add to dashboard Cite

show abstract

“…Los tipos de estudios incluidos fueron: fuentes primarias (trabajos aleatorizados y controlados) y secundarias (revisiones sistemáticas y metaanálisis). Las bases consultadas: PUBMED, SCOPUS y EMBASE y búsquedas manuales en NICE, AHR, SIGN, SMC, HTA de NIHR, CIGNA, AETNA, así como en Google (ASCO, ESMO, NCCN), CADTH [7][8][9][10][11][12][13][14][15] .…”

Section: Métodosunclassified

“…Además de las presentes recomendaciones se sugieren iniciativas complementarias que surgen del análisis de situación local y se tornan indispensables para el cumplimiento del protocolo [9][10][11][12] . La capacitación a médicos tratantes es fundamental para la consulta pre-test, solicitud de estudios y detección de casos con indicación de AGO tradicional [13][14][15] .…”

Section: Conclusiónunclassified

Protocolo sobre el rol del asesoramiento genético oncológico en el marco de oncología de precisión

Bruno,

Rodríguez Romero,

Winocur

et al. 2024

RevOnco

View full text Add to dashboard Cite

El Asesoramiento Genético Oncológico (AGO) es el proceso a través del cual se estratifica el riesgo genético de desarrollar cáncer de un individuo o grupo familiar y es un estándar de cuidado con comprobado beneficio. Recientemente, se sumó el desarrollo de drogas dirigidas específicamente a algunos tipos de tumores hereditarios, lo cual convierte a estas alteraciones genéticas en biomarcadores de tratamiento e incorpora el diagnóstico de cáncer hereditario a la práctica oncológica habitual. En consecuencia, las indicaciones actuales de estudios germinales exceden la sospecha clínica de cáncer hereditario y desafían a médicos tratantes a cubrir las implicancias heredo-familiares de estos casos. La realidad descripta plantea un cambio de paradigma en el modelo actual de AGO que debe ser modificado sin descuidar la calidad de atención brindada al paciente y para el que no existen recomendaciones oficiales actualmente disponibles en nuestro medio. Mediante un trabajo escalonado iniciado con una revisión sistemática de la evidencia actual de los últimos 10 años (trabajos aleatorizados, controlados, revisiones sistemáticas y metaanálisis), seguido de un diagnóstico de situación a través de una encuesta a profesionales involucrados en la temática en todo el país, se desarrolló un protocolo de recomendaciones sobre el rol del asesoramiento genético oncológico en el marco de la oncología de precisión. El protocolo está dirigido a médicos tratantes y aborda las distintas instancias del proceso de AGO (recomendaciones generales, específicas de instancia pre-test, de solicitud del estudio molecular germinal y específicas de instancia post-test). El presente trabajo genera pautas basadas en la mejor evidencia disponible que ayudan a sistematizar el accionar de los profesionales involucrados y promueve iniciativas colaborativas entre entidades gubernamentales de salud, decisores, sociedades médicas y entidades académicas de formación para asegurar el desarrollo formal de estos procesos de acción y cumplir con una adecuada estrategia de cuidado de tumores hereditarios en nuestra población.

show abstract

Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer

Vlaming,

Ausems,

Kiemeney

et al. 2024

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Background International guidelines recommend germline genetic testing for men with metastatic prostate cancer. If offered to all patients by genetic healthcare professionals, there will be insufficient capacity to cope with the high patient numbers. In a mainstreaming pathway, non-genetic healthcare professionals (ngHCPs) discuss and order germline genetic testing instead of referring patients to genetic healthcare professionals. We aimed to evaluate the experience of ngHCPs with pre-test genetic counselling and to explore the feasibility from the ngHCPs’ perspective. Methods We carried out a prospective cohort study in 15 hospitals in the Netherlands. All participating ngHCPs (i.e. urologists, medical oncologists, specialist nurses and nurse practitioners) completed an online training module of 45 min. The ngHCPs completed a questionnaire both before the training and at three and nine months after it. Paired analyses were used to compare the first with the last questionnaires on attitude, confidence in the ability to discuss and order germline genetic testing, and perceived and actual knowledge of genetics and genetic testing. Results 167 ngHCPs were invited to participate of whom 69 completed the first questionnaire and started or completed the last one. They had a positive attitude towards offering genetic testing themselves. After nine months of providing pre-test genetic counselling, significantly more ngHCPs considered mainstreaming helpful (94% after versus 81% before, p = 0.01). Both perceived and actual knowledge increased significantly. Pre-test genetic counselling took less than 10 minutes for 82% of ngHCPs and the majority (88%) were in favour of continuing the mainstream pathway. Only six participating ngHCPs considered mainstreaming possible without completing a training module beforehand. Conclusions After completing a short online training module, ngHCPs feel well-prepared to discuss germline genetic testing with metastatic prostate cancer patients.

show abstract

Patients’ experiences with pre-test genetic counseling provided by breast cancer healthcare professionals: Results from a large prospective multicenter study

Cited by 4 publications

References 28 publications

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline Q and A

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline Q and A

Protocolo sobre el rol del asesoramiento genético oncológico en el marco de oncología de precisión

Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer

Contact Info

Product

Resources

About